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A B S T R A C T
Purpose
This multicenter, open-label, phase II study evaluated the combination of bendamustine, gemci-
tabine, and vinorelbine (BeGEV) as induction therapy before autologous stem-cell transplantation
(ASCT) in patients with relapsed or refractory Hodgkin lymphoma (HL).
Patients and Methods
Patients with HL who were refractory to or had relapsed after one previous chemotherapy line were
eligible. The primary end point was complete response (CR) rate after four cycles of therapy.
Secondary end points were: overall response rate, stem-cell mobilization activity, and toxicity.
Progression-free and overall survival were also evaluated.
Results
In total, 59 patients were enrolled. After four cycles of therapy, 43 patients (73%) achieved CR, and
six (10%) achieved partial response, for an overall response rate of 83%. The most common grade
3 to 4 nonhematologic toxicities included febrile neutropenia (n = 7) and infection (n = 4). Regarding
hematologic toxicities, grade 3 to 4 thrombocytopenia and neutropenia were each experienced by
eight patients (13.5%). CD34+ cells were successfully harvested in 55 of 57 evaluable patients,
and 43 of 49 responding patients underwent ASCT. With a median follow-up of 29 months, the
2-year progression-free and overall survival rates for the total population were 62.2% and 77.6%,
respectively. The same ﬁgures for patients undergoing autograft were 80.8% and 89.3%,
respectively.
Conclusion
This phase II study demonstrates that BeGEV is an effective salvage regimen able to induce CR in
a high proportion of patients with relapsed or refractory HL before ASCT. These data provide a strong
rationale for further development of the BeGEV regimen.
J Clin Oncol 34:3293-3299. © 2016 by American Society of Clinical Oncology
INTRODUCTION
First-line chemoradiotherapy yields cure rates ap-
proaching 80% in patients with advanced-stage
Hodgkin lymphoma (HL).1,2 Patients who are
refractory to or relapse after initial therapy usually
have a worse prognosis, and second-line salvage
treatment programs are required as early as pos-
sible to reduce the risk of treatment failure, avoid
unnecessary toxicity, and prolong survival.3 Two
randomized, phase III studies conducted more
than 10 years ago showed an improved failure-free
survival rate with high-dose chemotherapy and
autologous stem-cell transplantation (ASCT) com-
pared with conventional-dose chemotherapy.4,5
However, the efﬁcacy of this approach has been
challenged by a recent meta-analysis.3 Therefore,
further investigation of the optimal therapeutic
strategy in patients with relapsed or refractory
HL seems warranted.6,7
Achieving complete response (CR) after
induction chemotherapy administered before
ASCTrepresents the strongest prognostic factor in
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patients receiving second-line salvage chemotherapy.8 Thus, in-
creasing the rate of CR achieved with induction chemotherapy
represents a primary goal in patients with refractory or relapsed HL.
Our group developed the IGEV regimen, consisting of ifos-
famide, gemcitabine, and vinorelbine, as pretransplantation sal-
vage chemotherapy.8 In a study of 91 patients, the overall response
rate (ORR) was 81%, with a 54% CR rate and no toxicity con-
cerns.8 Furthermore, the IGEV regimen demonstrated excellent
mobilizing potential of peripheral-blood stem cells.9
Bendamustine hydrochloride comprises a 2-chloroethylamine
alkylating group and a benzimidazole ring similar to cladribine.
Despite its structural similarities to both alkylating agents and
purine analogs, the exact mechanism of action of bendamustine
is unknown.10 Retrospective and prospective studies have shown
promising activity of bendamustine monotherapy in the treat-
ment of patients with multirelapsed HL who were ineligible
ASCTor for whom ASCT had failed, with a remarkable incidence
of CR (range, 25% to 35%).11-15 The use of bendamustine in
combination regimens as second-line salvage chemotherapy in
patients with relapsed or refractory HL has been proposed to
increase the CR rate.11 Therefore, in this multicenter phase II
study, we replaced ifosfamide in the IGEV regimen with
bendamustine to evaluate this combination (BeGEV) as in-
duction therapy before ASCT in patients with relapsed or re-
fractory HL.
PATIENTS AND METHODS
Patient Eligibility
Consecutive patients with HL age 18 years or older who were re-
fractory to or had relapsed after receiving one previous chemotherapy line
were eligible. Refractory disease was deﬁned as disease progression during
or within 3 months of doxorubicin-based chemotherapy, and relapsed
disease was deﬁned as reappearance of disease after CR lasting 3 months or
longer.16 Other inclusion criteria were as follows: Eastern Cooperative
Oncology Group performance status at2 or lower, at least one site of
measurable nodal disease at baseline of 1.5 cm or larger, absolute neu-
trophil count of 1.5 3 109/L or greater, platelet count of 75 3 109/L or
greater, and negative pregnancy test and agreement on using a method of
contraception for women. Patients were excluded if they had received
radiation therapy 3 weeks or less before study entry, had evidence of other
malignancies or history of malignancy within the 3 years before study
entry, had abnormal biochemical tests (creatinine $ 1.5 3 ULN,
bilirubin $ 1.5 3 ULN, or AST/ALT $ 2.5 3 ULN or $ 5.0 3 ULN if
transaminase elevation was due to disease involvement), or had ongoing
HIV, hepatitis B virus, or hepatitis C virus infection.
Setting and Study Design
This was a prospective, open-label, multicenter phase II study. Ten
centers from the Fondazione Italiana Linfomi (Italian Lymphoma
Foundation), located all over the Italian territory, participated in this study,
which started in September 2011 and ended in March 2014. The study was
conducted in accordance with the Helsinki Declaration; the ethical
committees of the participating centers approved the study protocol. All
patients signed an informed consent before inclusion.
Study Treatment
The BeGEV regimen consisted of gemcitabine 800 mg/m2 on days
1 and 4, vinorelbine 20 mg/m2 on day 1, and bendamustine 90 mg/m2 on
days 2 and 3. Prednisolone 100 mg per day was administered on days 1 to 4.
Patients received four cycles of the BeGEV regimen administered every
21 days. Growth factor support with granulocyte colony-stimulating factor
(G-CSF) was administered at each cycle. Patients received Pneumocystis
pneumonia prophylaxis and antiemetics in accordance with institutional
guidelines. Treatment was interrupted in case of disease progression,
unacceptable toxicity, or withdrawal of consent. Patients who achieved CR
or partial response (PR) after completion of the planned four cycles re-
ceived myeloablative therapy with BEAM (carmustine, etoposide, cytar-
abine, and melphalan; n = 20) or FEAM (fotemustine, etoposide,
cytarabine, and melphalan; n = 23) followed by reinfusion of mobilized
CD34+ circulating stem cells. BEAM consisted of carmustine 300 mg/m2
on day26, etoposide 200 mg/m2 on days25 to22, cytarabine 400 mg/m2
intravenously (IV) on days 25 to 22, and melphalan 140 mg/m2 IV on
day21. FEAMconsisted of fotemustine 150mg/m2 IVon days27 and26,
etoposide 200 mg/m2 on days 25 to 22, cytarabine 400 mg/m2 IV on
days 25 to 22, and melphalan 140 mg/m2 IV, on day 21. Both mye-
loablative regimens were followed by the reinfusion of at least 23 106 per
kilogram of body weight of CD34+ cells on day 0 and G-CSF 5 mg/kg
subcutaneously per day from day +5 until achievement of WBC of 3,000/mL
or greater for 3 days. Patients with residual lymphoma (. 1.5 cm on
computed tomography [CT] scan) at 100 days after ASCT received 30-Gy
involved-ﬁeld radiotherapy.
Response Criteria
Responses were assessed according to the International Working
Group response criteria.17 CT and [18F]ﬂuorodeoxyglucose–positron
emission tomography scans were performed before and after the fourth
BeGEV cycle. According to the 2007 criteria of Cheson et al,17 a metabolic
response was scored as CR when positron emission tomography scan
results were negative on the basis of visual analysis, independent from the
presence of residual masses on CT scan.
CD34+ Cell Mobilization and Collection
To elicit CD34+ cell mobilization, G-CSF (10mg/kg body weight) was
administered once per day beginning on day 7 and continued until
completion of the target cell harvesting (3 3 106 CD34+ cells/kg). Col-
lection of CD34+ cells was usually performed after the ﬁrst or second cycle,
when circulating CD34+ cells were 10/mL or greater using a COBE Spectra
separator (COBE, Lakewood, CO).
Data Analysis
The primary end point was CR proportion after four cycles of
therapy. Secondary end points were: ORR (ie, CR plus PR), stem-cell
mobilization activity, and toxicity (graded according to Common Ter-
minology Criteria for Adverse Events [version 4.0]). Progression-free
(PFS; calculated from ﬁrst BeGEVadministration to disease progression,
relapse, or death, whichever occurred ﬁrst, or until last disease assess-
ment for patient alive and without progressive disease) and overall
survival (OS; calculated from ﬁrst BeGEV administration to death or
last contact) were also evaluated. The sample size was estimated using
a Fleming’s single-stage phase II design. A CR proportion of 50% or
lower was considered to be clinically unworthy, whereas a proportion of
65% or higher would be assumed to be of potential interest. The drug
would be recommended for further study, with a 10% rejection error
(one sided) and a power of 85%, if 35 or more of the 59 total patients
were to achieve CR. Data were analyzed by descriptive statistics. Dif-
ferences between groups were estimated with the x2 or Fisher’s exact
test as appropriate. Kaplan-Meier survival curves were estimated, and
the log-rank test was used to assess survival differences. The univariable
Cox proportional hazards regression model was used to calculate hazard
ratios (HRs) with 95% CIs. Statistical signiﬁcance was set at P less
than .05 (two sided) for all secondary evaluations. Statistical analysis
was performed using STATA software (version 13; STATA, College
Station, TX).
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RESULTS
Patient Characteristics
Between September 2011 and March 2014, 59 patients were
enrolled (Table 1; Fig 1). The median age was 33 years (range, 18 to
68 years), and 31 patients (53%) were men. Fifty-six patients
(95%) had received ABVD (doxorubicin, bleomycin, vinblastine,
and dacarbazine) as ﬁrst-line therapy, and three (5%) had received
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophospha-
mide, vincristine, procarbazine, and prednisolone). Overall, 27
patients (46%) were refractory to and 32 (54%) had experienced
relapse after ﬁrst-line treatment (22 within and 10 after 12 months).
Of the 59 patients, one was not evaluable for response. This pa-
tient discontinued the study after two cycles of BeGEV because
of psychiatric and behavioral problems while he was in clinical
response; he was subsequently monitored and died as a result of
disease progression.
Treatment Response and ASCT
By intention to treat, after four cycles of therapy, 43 patients
(73%) achieved CR, and six (10%) achieved PR, for an ORR of
83% (49 of 59; Fig 1). One patient (2%) had stable disease, eight
patients (14%) experienced disease progression, and one patient
(2%) was not evaluable for response (Table 2). In univariable
analysis, the only factor associated with a different probability of
achieving CR was disease status at study entry, with CR being
achieved by 84% of patients with relapsed disease and 59% of those
with refractory disease (P = .031; Table 2). Of the 49 responding
patients, 43 (73% by intention to treat) proceeded to ASCT (38 of
43 achieving CR and ﬁve of six achieving PR); the remaining six
patients did not proceed to ASCT because of mobilization failure
(n = 2), physician decision (n = 2), early relapse (n = 1), and
patient refusal (n = 1).
Survival Analysis
PFS and OS Kaplan-Meier curves for all patients are shown in
Figs 2A and 2B. With a median follow-up of 29.1 months (range,
3.4 to 49.1 months), the 2-year PFS and OS rates were 62.2% and
77.6%, respectively. No differences were observed when main
prognostic factors were analyzed. In particular, response to ﬁrst-
line chemotherapy did not signiﬁcantly inﬂuence prognosis, with
a 2-year PFS of 62.5% veresus 62.3% (P = .769) and 2-year OS of
79.7% versus 75.9% (P = .645) for patients with relapsed and
refractory disease, respectively (Figs 2C and 2D). The 2-year PFS
and OS rates for patients receiving an autograft during CR or PR
were 80.8% and 89.3%, respectively (Figs 2E and 2F).
CD34+ Cell Mobilization and Harvesting
Fifty-seven of 59 patients were evaluable for CD34+ cell
mobilization. Two patients were excluded: one because of medical
decision and one for stem-cell collection before study inclusion.
After BeGEV, the median peak value of CD34+ cells (89 cells/mL;
range, 1 to 763 cells/mL) was recorded on day 12. Mobilization
failure was detected in two (3.5%) of 57 patients; CD34+ cells were
successfully harvested in 55 (96.5%) of 57 evaluable patients.
Forty-two patients (76%) required one leukapheresis to harvest the
planned target CD34+ cell yield (3 3 106 CD34+ cells/kg body
Table 1. Patient Demographic and Clinical Characteristics (N = 59)
Characteristic No. %
Age, years
Median 33
Range 18-68
Sex
Male 31 53
Female 28 48
Response to primary therapy
Relapsed disease 32 54
CR , 1 year 22 37
CR $ 1 year 10 17
Primary refractory 27 46
Extranodal sites of disease
Yes 24 41
No 35 59
Prior radiotherapy
Yes 9 15
No 50 85
Prior chemotherapy
ABVD 56 95
BEACOPP 3 5
NOTE. Sums of percentages may not be equal to 100% as a result of rounding.
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine;
BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisolone; CR, complete response.
Enrolled       (N = 59)
Completed four cycles of BeGEV          (n = 58)
CR    (n = 43) PR    (n = 6) PD  (n = 8) SD  (n = 1)
Not assessable for response
because of psychiatric 
problems                     (n = 1) 
ASCT     (n = 38) ASCT     (n = 5)
Did not proceed to ASCT
Did not proceed to ASCT
   Physician decision (n = 1)
Mobilization failure
Physician decision
Early relapse
Patient refusal
(n = 2)
(n = 1)
(n = 1)
(n = 1)
Fig 1. Diagram showing the ﬂow of participants. ASCT, autologous stem-cell
transplantation; BeGEV, bendamustine, gemcitabine, and vinorelbine; CR, com-
plete remission; PD, progressive disease; PR, partial remission; SD; stable
disease.
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weight), whereas 13 patients (24%) required two leukaphereses.
The median total yield of CD34+ cells per kilogram of body weight
was 8.83 106 CD34+ cells (range, 3 to 563 106 cells). After ASCT,
engraftment of neutrophils and platelets was recorded on median
day 11 (range, day 9 to 21) and median day 12 (range, day 9 to 26),
respectively.
Toxicity
Adverse events are listed in Table 3. The most common
nonhematologic toxicities included grade 1 to 2 nausea, infection,
and febrile neutropenia as well as grade 3 to 4 febrile neutropenia
(n = 7) and infection (n = 4). Among hematologic toxicities, grade
3 to 4 thrombocytopenia and neutropenia were each experienced
by eight patients. Of 223 evaluated cycles, 69 cycles (31%) were
delayed because of hematologic toxicity (n = 4), nonhematologic
toxicity (n = 5), infection (n = 6), patient-related logistic reasons
(n = 49), and other reasons (n = 5). Dose reductions were recorded
in 19 cycles (9%) because of poor performance status (n = 1),
neutropenia (n = 1), vertigo (n = 1), body weight changes (n = 12),
and unknown reasons (n = 4). RBC transfusions were required by
14% (n = 8) and platelet transfusions by 5% of patients (n = 3),
respectively. Overall, the median dose-intensity per cycle was more
than 98%.
DISCUSSION
This is the ﬁrst phase II trial to our knowledge reporting efﬁcacy
and toxicity data of a novel bendamustine-containing regimen,
namely the BeGEV regimen, administered in an outpatient setting
to ASCT-eligible patients with HL who were refractory to or ex-
perienced relapse after ﬁrst-line chemotherapy. Notwithstand-
ing the poor prognostic features of study patients, including
primary chemotherapy refractoriness (47%), CR duration of less
than 1 year (37%), and extranodal disease (41%), the analysis of
clinical response clearly shows the remarkable efﬁcacy of this
bendamustine-containing regimen as well as its favorable toxicity
proﬁle. Notably, the BeGEV regimen induced a 73% CR pro-
portion, which was far higher than the threshold applied to deﬁne
clinical interest (65%). This CR rate is substantially higher than
that reported for the IGEVregimen (73% v 54%)8 and has never to
our knowledge been observed using a variety of second-line salvage
regimens (eg, ICE [ifosphamide, carboplatin, and etoposide],18
DHAP [dexamethasone, cisplatin, and cytarabine],19 or GDP
[gemcitabine, dexamethasone, and cisplatin]20) before ASCT.
Additionally, 88% of the patients who responded to the BeGEV
regimen were able to proceed to ASCT, showing 2-year PFS and OS
rates of 81% and 89%, respectively.
Despite the sample size of our study, which did not allow
performance of a multivariable analysis, it seems that completion
of the salvage program (BeGEV plus ASCT) overcame the negative
prognostic impact of disease status before BeGEV, as shown by lack
of signiﬁcant differences in terms of 2-year PFS and OS in patients
with relapsed or refractory disease. However, future studies with
larger series will be required to address this issue deﬁnitively.
The BeGEV regimen had excellent stem-cell mobilization
activity, with only two mobilization failures detected in more than
57 mobilized patients. All patients experienced full hematopoietic
engraftment, strongly supporting that BeGEV-mobilized CD34+
cells are fully functional. Thus, these results not only clearly
demonstrate that the BeGEV regimen has potent stem-cell mo-
bilizing activity, but also demonstrate that bendamustine does not
have any detrimental effect on stem-cell mobilization or stem-cell
engraftment.
BeGEV showed a favorable toxicity proﬁle, characterized by
limited occurrence of grade 3 to 4 nonhematologic and hema-
tologic toxicities, similar to that observed with the IGEV regimen,
without hemorrhagic cystitis. Even more interestingly, BeGEV was
administered as an outpatient regimen, further supporting an
advantage over other regimens, including IGEV,8 DHAP,19 and
ICE18 regimens, which require hydration and hospitalization.
Recently, a variety of novel agents have become available for
transplantation-eligible patients with HL as well as patients with
relapsed or refractory HL,21 thus raising the question of whether to
incorporate novel agents into conventional chemotherapy regi-
mens or compare these two treatment modalities to optimize
treatment strategies for relapsed and refractory HL. Unprecedented
efﬁcacy data have been reported for novel agents such as bren-
tuximab vedotin,22-26 nivolumab,27-29 and pembrolizumab,30,31
which target tumor or microenvironmental cells through dis-
tinct mechanisms of action. Novel agents have mainly been ex-
plored in the setting of ASCT failure, and their use has resulted in
CR rates that are far below those observed with the BeGEVregimen
in the pretransplantation setting; in contrast, limited data are
available on the use of new agents in the pretransplantation
Table 2. Clinical Responses to BeGEV Regimen According to ITT and Disease Status at Entry
Parameter No. of Patients
CR PR SD PD NE
No. % No. % No. % No. % No. %
Response by ITT 59 43 73 6 10 1 2 8 14 1 2
Disease status at study entry
Relapsed 32 27 84* 3 9 1 3 0 0 1 3
Refractory 27 16 59* 3 11 0 0 8 30 0 0
NOTE. One patient discontinued the study after two cycles of BeGEV because of psychiatric and behavioral problems while he was clinically responding. Two patients
were evaluated after the third cycle (but not the fourth), but they continued the study according to protocol. Sums of percentagesmay not be equal to 100% as a result of
rounding.
Abbreviations: BeGEV, bendamustine, gemcitabine, and vinorelbine; CR, complete response; ITT, intention to treat; NE, not evaluable; PD, progressive disease; PR,
partial response; SD, stable disease.
*P = .031 (CR v other).
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Fig 2. Kaplan-Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) of the overall population, (C) PFS and (D) OS of patients with relapsed or
refractory disease before BeGEV (bendamustine, gemcitabine, and vinorelbine), and (E) PFS and (F) OS of patients who achieved complete or partial response and
underwent autologous stem-cell transplantation.
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setting.32-34 Nonetheless, such cross-trial comparisons do not
permit ﬁrm conclusions to be made regarding the relative efﬁcacy
of brentuximab vedotin or nivolumab as compared with the
BeGEV regimen.
In conclusion, the results of this multicenter phase II study
demonstrate that BeGEV is an effective salvage regimen able to
induce CR in a high proportion of patients with relapsed or re-
fractory HL before ASCT. These ﬁndings provide a strong rationale
for further development of the BeGEV regimen. Because the
number of novel agents that may be added in the pre-
transplantation therapy setting is growing, direct comparisons of
combinations incorporating novel agents with BeGEV and other
regimens will be necessary to identify the best salvage strategy for
relapsed and refractory HL.
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